演題詳細

ポスター / Poster

ポスター 36 (Poster 36) :骨髄腫:その他

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
池田 宇次 (Takashi Ikeda):1
1:静岡県立静岡がんセンター 血液・幹細胞移植科
 
前へ戻る

Overall survival of patients with symptomatic multiple myeloma

演題番号 : PS-1-269

澤村 守夫 (Morio Sawamura):1、小屋 紘子 (Hiroko Koya):1、大崎 洋平 (Yohei Osaki):1、宮澤 悠里 (Yuri Miyazawa):1、磯田 淳 (Atsushi Isoda):1、松本 守生 (Morio Matsumoto):1、半田 寛 (Hiroshi Handa):2、齋藤 貴之 (Takayuki Saitoh):3、村上 博和 (Hirokazu Murakami):3

1:Nishigunma National Hospital, Shibukawa, Japan、2:Gunma University Graduate School of Medicine, Maebashi, Japan、3:Gunma University Graduate School of Health Science, Maebashi, Japan

 

Background: Novel agents has changed the management of myeloma patients dramatically. We inspected whether overall survival (OS) of myeloma patients was improved. Patients and methods: We retrospectively analyzed consecutive patients with newly diagnosed symptomatic myeloma who started treatment between 1996 and 2010 in. For examination of the time trends, we grouped the time interval into two year periods, 1996-2004 and 2005-2010. Results: Of 256 myeloma patients, 39.8% were in the 1996-2004 group. The median age at diagnosis was 66 years (range 36-89). 31.6% underwent ASCT. Thalidomide (27.3%), bortezomib (34%), and lenalidomide (20.7%) were used in relapsed and refractory myeloma setting. Median follow-up of these patients was 2.4 months. The median OS for all patients is 3.9 years (95% CI; 3.1, 4.7). The median OS for the 1996-2004 group was 4.1 years compared with 3.6 years for the 2005-2010 group (P= 0.679). No significant differences were observed between the 1996-2004 group and the 2005-2010 group in terms of age or ISS stage. The mean OS of transplant ineligible patients treated with one or more novel agents is 4.6 years (95% CI; 3.4, 5.7) compared with 1.7 years for patients without novel agents (95% CI; 1.2, 2.1) (P<0.001). In the transplant eligible patients, no significant differences were obtained among them (6.3 years vs. 4.9 years). Conclusions: Treatment with novel agents increases and it is used for relapsed and refractory myeloma mainly, but has not yet led to improvement of OS of many patients with multiple myeloma.

前へ戻る